Foghorn Therapeutics Inc. (FHTX) Spending and interest coverage
- R&D / revenue · 12 months: Value 214.57%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 26.97%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 214.57% | Research and development expense / revenue. Period ending 2026-06-30. $78.83M ÷ $36.74M × 100 ≈ 214.57% |
| Stock-based compensation / revenue · 12 months | 26.97% | Share-based compensation / revenue. Period ending 2026-06-30. $9.91M ÷ $36.74M × 100 ≈ 26.97% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 78.83M USD | Research and Development Expense |
| Revenue | 36.74M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.91M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -72.76M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $78.83M | $36.74M | $9.91M | $-72.76M | (m) | 214.57% | 26.97% | (m) | (m) |
| 2026-03-31 | $82.10M | $28.22M | $10.09M | $-85.05M | (m) | 290.88% | 35.75% | (m) | (m) |
| 2025-12-31 | $85.47M | $30.91M | $10.40M | $-86.39M | (m) | 276.51% | 33.64% | (m) | (m) |
| 2025-09-30 | $83.93M | $24.52M | $10.64M | $-86.52M | (m) | 342.31% | 43.40% | (m) | (m) |
| 2025-06-30 | $88.61M | $24.17M | $10.93M | $-91.87M | (m) | 366.59% | 45.20% | (m) | (m) |
| 2025-03-31 | $90.62M | $23.50M | $11.36M | $-97.40M | (m) | 385.55% | 48.34% | (m) | (m) |
| 2024-12-31 | $94.53M | $22.60M | $11.89M | $-102.68M | (m) | 418.23% | 52.62% | (m) | (m) |
| 2024-09-30 | $98.22M | $25.52M | $12.46M | $-104.14M | (m) | 384.97% | 48.84% | (m) | (m) |
| 2024-06-30 | $99.79M | $35.19M | $13.54M | $-97.36M | (m) | 283.61% | 38.47% | (m) | (m) |
| 2024-03-31 | $105.24M | $33.90M | $14.84M | $-102.78M | (m) | 310.47% | 43.78% | (m) | (m) |
| 2023-12-31 | $109.69M | $34.16M | $16.19M | $-107.91M | (m) | 321.15% | 47.39% | (m) | (m) |
| 2023-09-30 | $113.69M | $32.57M | $16.92M | $-114.33M | (m) | 349.07% | 51.94% | (m) | (m) |
| 2023-06-30 | $114.37M | $21.73M | $16.62M | $-125.51M | (m) | 526.42% | 76.52% | (m) | (m) |
| 2023-03-31 | $111.09M | $20.62M | $15.66M | $-122.65M | (m) | 538.85% | 75.98% | (m) | (m) |
| 2022-12-31 | $105.62M | $19.23M | $14.34M | $-117.14M | (m) | 549.29% | 74.56% | (m) | (m) |
| 2022-09-30 | $99.87M | $15.76M | $12.64M | $-113.33M | $426.00K | 633.83% | 80.21% | -266.04× | Reported |
| 2022-06-30 | $93.44M | $9.16M | $11.21M | $-111.33M | $925.00K | 1019.63% | 122.29% | -120.36× | Reported |
| 2022-03-31 | $86.11M | $4.95M | $9.74M | $-105.41M | $1.42M | 1738.48% | 196.65% | -74.23× | Reported |
| 2021-12-31 | $80.33M | $1.32M | $8.38M | $-100.73M | $1.91M | 6089.84% | 635.63% | -52.85× | Reported |
| 2021-09-30 | $74.33M | $857.00K | $7.38M | $-93.43M | $1.80M | 8673.63% | 860.56% | -51.88× | Reported |
| 2021-06-30 | $69.95M | $995.00K | $5.88M | $-85.66M | $1.50M | 7030.35% | 591.46% | -56.95× | Reported |
| 2021-03-31 | $64.94M | $716.00K | $4.33M | $-77.94M | $1.21M | 9069.55% | 605.03% | -64.57× | Reported |
| 2020-12-31 | $57.72M | $430.00K | $2.96M | $-68.53M | $979.00K | 13422.09% | 688.60% | -70.00× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $44.36M | (m) | $1.69M | $-51.08M | $540.00K | (m) | (m) | -94.60× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |